-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623.O1.6 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I Clinically Relevant Abstract

Symposia: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, non-Hodgkin lymphoma, Lymphomas, Non-Biological therapies, Bispecific Antibody Therapy, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, Diseases, indolent lymphoma, Therapies, Immunotherapy, aggressive lymphoma, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
La Nouvelle Orleans Ballroom C (Ernest N. Morial Convention Center)
Moderators:
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis and Martin Dreyling, MD, University Hospital, LMU Munich
Disclosures:
Kahl: Janssen: Consultancy; Kite: Consultancy; Beigene: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding; Pharmacyclics: Consultancy; AcertaPharma: Consultancy; MEI: Consultancy; Abbvie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Roche: Consultancy; ADT Therapeutics: Consultancy; AstraZeneca: Consultancy, Research Funding; Incyte: Consultancy; Hutchmed: Consultancy, Research Funding; TG Therapeutics: Consultancy; Genmab: Consultancy; Seattle Genetics: Consultancy; Research To Practice: Speakers Bureau. Dreyling: Lilly/Loxo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead/Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Abbvie: Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy.
This session predominantly focuses on the interventional studies in the mantle cell lymphoma
9:30 AM

Jia Ruan, MD, PhD1, John P. Leonard, MD2, Gui Zhen Chen3*, Zhengming Chen, PhD, MPH1*, John N. Allan1, Sarah C. Rutherford, MD1, Brittany Hobbie, MPH1*, Katie Greig1*, Amelyn Rodriguez, BSN, RN, OCN1*, Wayne Tam, MD, PhD4, David A. Bond, MD, BS5, Bijal D. Shah, MD6, Kami J. Maddocks, MD7, Bhavneet Binder1*, Giorgio Inghirami, MD4*, Olivier Elemento, PhD8*, Selina Chen-Kiang, PhD4 and Peter Martin, FRCPC, MD, MS9

1Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
2Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
3Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York
4Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
6Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
7Ohio State University Hospital, Columbus, OH
8Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY
9Meyer Cancer Center, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY

9:45 AM

Tycel J. Phillips, MD1, Michael Dickinson, MD2, Franck Morschhauser, MD, PhD3*, Emmanuel Bachy, MD, PhD4*, Michael Crump5, Marek Trněný6, Nancy L. Bartlett7, Jan Zaucha8*, Tomasz Wrobel9*, Fritz Offner, MD, PhD10, Kathryn Humphrey11*, Linda Lundberg12*, James Relf11*, Audrey Filézac de L'Étang12*, David Carlile11*, Ben Byrne11*, Naseer Qayum11* and Carmelo Carlo-Stella, MD, PhD13

1University of Michigan Medical School, Ann Arbor, MI
2Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia
3Hematology Department, Lille University Hospital, Lille, France
4Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France
5Princess Margaret Hospital, Toronto, ON, Canada
61st Fac Medicine, Charles University, General Hospital, Prague, Czech Republic
7Siteman Cancer Center, Washington University, St. Louis, MO
8Medical University of Gdańsk, Gdańsk, Poland
9Wroclaw Medical University, Wroclaw, Poland
10Dept Hematology Universitair Ziekenhuis, Gent, Belgium
11Roche Products Ltd, Welwyn Garden City, United Kingdom
12F. Hoffmann-La Roche Ltd, Basel, Switzerland
13Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

10:00 AM

Adrian Minson, MBBS1,2,3, Nada Hamad, MBBS, BSc, MSc4, Chan Yoon Y. Cheah, MD5,6, Constantine S. Tam, MD, MBBS1,3,7,8, Piers Blombery, MBBS1,2,3, David A Westerman, MBBS, FRCPA, FRACP1,2,3, Stephen Lade2*, David Ritchie, MB ChB, PhD1,2,3,9, Rachel M Koldej, PhD1,3,9*, Mary Ann Anderson, MBBS, PhD1,2,3,10, Amit Khot, MBBS, MD2,3, John F. Seymour, MBBS, PhD, FRACP1,2,3, Molly Robertson, MN2*, Imogen R Caldwell, FRACP, FRCPA2, Georgina L Ryland, PhD1,2, Jing Xie, PhD2*, Huw Morgan, BSc1,11* and Michael Dickinson, MD1,2,3

1University of Melbourne, Melbourne, Australia
2Peter MacCallum Cancer Centre, Melbourne, Australia
3Royal Melbourne Hospital, Melbourne, Australia
4St Vincent's Hospital, Sydney, NSW, Australia
5Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, WEA, Australia
6University of Western Australia, Crawley, Australia
7Peter MacCallum Cancer Centre, Kew, VIC, Australia
8Alfred Hospital, Melbourne, Australia
9ACRF Translational Research Laboratory, Royal Melbourne Hospital, Parkville, VIC, Australia
10The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
11ACRF Translational Research Laboratory, Melbourne, Australia

10:15 AM

Mats Jerkeman, MD, PhD1, Arne Kolstad, MD, PhD2*, Martin Hutchings, MD, PhD3*, Annika Pasanen, MD, PhD4*, Leo Meriranta, MD5*, Carsten Utoft Niemann, MD, PhD6, Rasmus Rask Kragh Jørgensen7*, Tarec Christoffer Christoffer El-Galaly, MD, DSc8, Jon Riise, MD, PhD9*, Sirpa Leppä, MD, PhD10*, Jacob Haaber Christensen, MD, PhD11*, Karin Fahl Wader, MD, PhD12* and Ingrid Glimelius, MD, PhD13*

1Department of Oncology, Lund University and Skane University Hospital, Lund, Sweden
2Sykehuset Innlandet, Lillehammer, Norway
3Rigshospitalet, Copenhagen, Denmark
4Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland
5University of Helsinki and Helsinki University Hospital, Helsinki, Finland
6Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
7Aalborg University, Aalborg, Denmark
8Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
9Oslo University Hospital, Oslo, NOR
10Department of Oncology, Helsinki University Hospital Cancer Center, Helsinki, FIN
11Odense University Hospital, Odense, Denmark
12Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
13Department of Immunology, Genetics, and Pathology, Clinical and Experimental Oncology, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden

10:30 AM

Mitchell R Smith, MD1, Opeyemi Jegede, PhD2*, Peter Martin, FRCPC, MD, MS3, Brian G. Till, MD4, Samir Parekh, MD5, David T. Yang, MD6, Lale Kostakoglu, MD, MPH7*, Carla Casulo, MD8, Nancy Bartlett9*, Paolo F Caimi, MD10, Tareq Al Baghdadi, MD11*, Kami J. Maddocks, MD12, Mark D. Romer13*, David J. Inwards, MD14, Rachel E. Lerner, MD, MS15*, Lynne I. Wagner, PhD16*, Richard Little, MD17*, Jonathan W. Friedberg, MD, MMSc18, John P. Leonard, MD19 and Brad S. Kahl, MD20

1The Follicular Lymphoma Foundation, Washington, DC
2Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston
3Meyer Cancer Center, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY
4Division of Hematology and Medical Oncology, University of Washington, Seattle, WA
5Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
6University of Wisconsin - Medical School, Madison, WI
7University of Virginia, Charlottesville, VA
8University of Rochester Medical Center, Rochester, NY
9Washington University Sch. of Med. Siteman Cancer Center, Saint Louis, MO
10Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
11IHA Hematology Oncology Consultants, Ypsilanti, MI
12Ohio State University Hospital, Columbus, OH
13Good Samaritan Hospital, Kettering, OH
14Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
15Saint Louis Park, Park Nicollet Clinic, Saint Louis Park, MN
16Wake Forest School of Medicine, Winston Salem, NC
17Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD
18James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
19Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
20Division of Oncology, Washington University School of Medicine in St. Louis, Saint Louis, MO

10:45 AM

Jacob D. Soumerai, MD1, Catherine S. Diefenbach, MD2, Felipe Samaniego, MD3, Abhijeet Kumar4*, Michaela L. Tsai5*, Adam S. Asch, MD6, Deepa Jagadeesh, MD7, Vaishalee P. Kenkre, MD8, Izidore S. Lossos, MD9, Huda Salman, MD, PhD10*, Farrukh T. Awan, MD11, Lu Miao12*, Richard G. Ghalie, MD12* and Andrew D. Zelenetz, MD, PhD13

1Center for Lymphoma, Massachusetts General Hospital, Boston, MA
2New York University School of Medicine, NYU Cancer Institute, New York, NY
3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ
5Swedish Cancer Institute, Seattle, WA
6Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
7Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Carbone Cancer Center, University of Wisconsin, Madison, WI
9Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
10Stony Brook University Hospital, Stony Brook, NY
11University of Texas Southwestern Medical Center, Dallas, TX
12MEI Pharma, Inc., San Diego, CA
13Memorial Sloan Kettering Cancer Center, New York, NY

*signifies non-member of ASH